Dr. Susan Galbraith

So it's overall a 56% rate of crossover onto Ascent.

In the tropium breast O2 study, around 30% of patients ended up on a second line antibody drug conjugate, either a trop2 or a HER2 directed antibody drug conjugate.

So the rates of crossover aren't as high

The difference between those aren't as big as perhaps, you know, people when they react to the 80% number first thing is, you know, and what we saw is even though we got a 30% crossover is still translated through to an improvement in this overall

survival number.

And I think that's those sets of data, high response rate, good durability of response, leading to progression-free survival of five months and a five-month improvement in overall survival.

The totality of those data really have a compelling argument that this is the best-in-class trope to ADC.

And it's great to have an option for patients in a segment of the disease where there hasn't been an improvement for over a decade.

So it's very exciting.

Yeah, sure.

So you're absolutely right that over time physicians learn to deal with the side effects of treatment.

And actually the breast cancer physicians have had other drugs that they've had experience with stomatitis with some of the PI3 kinase inhibitors, for example.

Yes, stomatitis is clearly seen.

It can be managed with either ice chips during the period of the infusion in the mouth or with a corticosteroid mouthwash.

Both of those as management techniques on the experience of investigators are reducing the impact of the stomatitis.

Obviously, it's important that

patients and their caregivers understand what those opportunities are for improving to this.

And for some patients, it does become an issue.

But for the majority of patients, it hasn't prevented them from taking Datraway.

There's a very low rate of discontinuation due to stomatitis on the Datraway studies.